Cover Image

Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer

People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour (TURBT). Mitomycin C (MMC) and Bacillus Calmette‐Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate‐ or high‐risk no...

Full description

Saved in:
Bibliographic Details
Main Authors: Hahne, Stefanie (Author) , Kunath, Frank (Author) , Coles, Bernadette (Author) , Draeger, Desiree Louise (Author) , Krabbe, Laura-Maria (Author) , Dersch, Rick (Author) , Kilian, Samuel (Author) , Jensen, Katrin (Author) , Dahm, Philipp (Author) , Meerpohl, Joerg J. (Author)
Format: Article (Journal)
Language:English
Published: 08 January 2020
In: The Cochrane database of systematic reviews
Year: 2020, Issue: 1
ISSN:1469-493X
DOI:10.1002/14651858.CD011935.pub2
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1002/14651858.CD011935.pub2
Verlag, lizenzpflichtig, Volltext: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011935.pub2/full
Get full text
Author Notes:Stefanie Schmidt, Frank Kunath, Bernadette Coles, Desiree Louise Draeger, Laura-Maria Krabbe, Rick Dersch, Samuel Kilian, Katrin Jensen, Philipp Dahm, Joerg J. Meerpohl
Description
Summary:People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour (TURBT). Mitomycin C (MMC) and Bacillus Calmette‐Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate‐ or high‐risk non‐muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain.
Item Description:Gesehen am 03.04.2020
Physical Description:Online Resource
ISSN:1469-493X
DOI:10.1002/14651858.CD011935.pub2

Similar Items